Compare KRMD & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | MDWD |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 230.7M |
| IPO Year | N/A | 2014 |
| Metric | KRMD | MDWD |
|---|---|---|
| Price | $5.77 | $19.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.83 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 193.5K | 95.0K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | $20,932,000.00 |
| Revenue This Year | $23.36 | $15.89 |
| Revenue Next Year | $18.63 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | 6.15 |
| 52 Week Low | $1.86 | $14.14 |
| 52 Week High | $6.11 | $22.51 |
| Indicator | KRMD | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 69.43 | 59.99 |
| Support Level | $5.52 | $18.71 |
| Resistance Level | $6.11 | $19.63 |
| Average True Range (ATR) | 0.41 | 0.71 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 76.92 | 79.22 |
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.